Abstract
Purpose :
Ocular surface diseases pose significant challenges in clinical trials due to the complexity of assessing treatment efficacy and disease progression. Utilizing advanced imaging tools in interventional randomized clinical trials presents a promising avenue for enhancing our understanding and assessment of these diseases. This study aims to demonstrate the clinical applicability of innovative imaging modalities, including in-vivo confocal microscopy, anterior segment OCT (AS-OCT), and ocular surface analyser (OSA), in the context of interventional trials for ocular surface diseases.
Methods :
This study focused on the presentation and demonstration of advanced imaging modalities in the context of their application to ocular surface diseases. Considering clinical cases, we showcased the capabilities and functionalities of these imaging tools when novel treatments are considered for ocular surface diseases.
Results :
In-vivo confocal microscopy was utilized to illustrate its ability to capture high-resolution images of the ocular surface layers, demonstrating its potential for cellular-level imaging and visualizing pathological changes associated with ocular surface diseases. AS-OCT was employed to showcase its capacity to provide detailed cross-sectional imaging of the anterior segment and to monitor the treatments’ effects, emphasizing its role in assessing structural changes and potential applications in monitoring disease progression. The OSA was used to simulate and analyse tear film dynamics, highlighting its contributions towards comprehensive assessment and understanding of ocular surface health.
Conclusions :
This demonstration focused on highlighting the capabilities of advanced imaging tools, including in-vivo confocal microscopy, AS-OCT, and OSA, when investigative medicinal products are considered in ocular surface disease patients. These simulated presentations underscored the potential of these technologies in improving diagnostic capabilities and understanding ocular surface diseases, offering a glimpse into their potential application in future clinical settings for enhancing patient care and outcomes.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.